CTMC
Accelerating Cell Therapies for Cancer Treatment
The University of Texas MD Anderson Cancer Center and National Resilience, Inc., formed CTMC in May 2022, a joint venture to accelerate the development and manufacturing of impactful cell therapies for patients with cancer. CTMC’s 60,000 sq. ft. GMP facility with 14 cleanrooms, is located in the Texas Medical Center within walking distance to the MD Anderson clinic. The relationship and proximity between manufacturing and the clinic enables the seamless coordination required for efficient cell therapy that begins and ends with the patient. As therapies proceed into later-stage clinical trials and commercialization, CTMC can gradually transition manufacturing to Resilience’s broad digitally connected network to quickly scale up to meet patient needs.
CTMC is focused on addressing the unmet clinical needs of patients with cancer who have not been successfully treated with chemotherapy and radiation. Their expertise is in tumor infiltrating lymphocytes (TILs), CAR-T therapies, endogenous T-cells (ETC), and natural killer (NK) cells. Significant investment has been made in the transition from paper to integrated IT systems with implementation of five platforms designed to increase efficiency, improve quality, standardize processes, and allow for greater collaboration.
In the past 18 months, CTMC has successfully navigated six novel cell therapies through Investigational New Drug (IND) clearance including OBX-115: the novel TIL therapy from Obsidian Therapeutics; IVS-3001: the anti-HLA-G CAR-T therapy from Invectys; and most recently, KSQ-001EX: the lead engineered CRISPR/CAS9 TIL therapy from KSQ Therapeutics to treat solid tumors. In June, CTMC was awarded $9.1M as the first recipient of the newly created Cancer Prevention & Research Institute of Texas (CPRIT) Texas New Technologies Company grant to create advanced development and manufacturing technologies.
